top of page

Educational Resources

Please see the list below of selected publications relevant to each section. If you are a researcher or student interested in any of these topics, please feel free to reach out. 

Psychedelics

Psilocybin

Depression

[1] Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022;387(18):1637-1648. doi:10.1056/NEJMoa2206443

[2] Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021;384(15):1402-1411. doi:10.1056/NEJMoa2032994

[3] Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial [published correction appears in JAMA Psychiatry. 2021 Feb 10;:]. JAMA Psychiatry. 2021;78(5):481-489. doi:10.1001/jamapsychiatry.2020.3285

[4] Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord. 2023;327:120-127. doi:10.1016/j.jad.2023.01.108

[5] Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-627. doi:10.1016/S2215-0366(16)30065-7

[6] Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018;235(2):399-408. doi:10.1007/s00213-017-4771-x

[7] Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-627. doi:10.1016/S2215-0366(16)30065-7

[8] Daws RE, Timmermann C, Giribaldi B, et al. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022;28(4):844-851. doi:10.1038/s41591-022-01744-z

[9] Sloshower J, Skosnik PD, Safi-Aghdam H, et al. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. J Psychopharmacol. 2023;37(7):698-706. doi:10.1177/02698811231154852

 

Addiction/substance misuse

[1] Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983-992. doi:10.1177/0269881114548296

[2] Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289-299. doi:10.1177/0269881114565144

[3] Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial [published correction appears in JAMA Psychiatry. 2022 Sep 14;:]. JAMA Psychiatry. 2022;79(10):953-962. doi:10.1001/jamapsychiatry.2022.2096

 

Anxiety & end-of-life psychiatric distress/anxiety

[1] Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197. doi:10.1177/0269881116675513

[2] Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165-1180. doi:10.1177/0269881116675512

[3] Becker AM, Holze F, Grandinetti T, et al. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clin Pharmacol Ther. 2022;111(4):886-895. doi:10.1002/cpt.2487

​

Bipolar disorder Type II

[1] Aaronson ST, van der Vaart A, Miller T, et al. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Controlled Trial [published correction appears in JAMA Psychiatry. 2024 Apr 10;:]. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2023.4685

​

Obsessive-compulsive disorder (OCD)

[1] Kelmendi B, Kichuk SA, DePalmer G, et al. Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon. 2022;8(12):e12135. Published 2022 Dec 6. doi:10.1016/j.heliyon.2022.e12135

[2] Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735-1740. doi:10.4088/jcp.v67n1110

​

Lysergic acid diethylamide (LSD)

Depression

[1] Molla H, Lee R, Tare I, de Wit H. Greater subjective effects of a low dose of LSD in participants with depressed mood. Neuropsychopharmacology. 2024;49(5):774-781. doi:10.1038/s41386-023-01772-4

​

Anxiety & end-of-life psychiatric distress/anxiety

[1] Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513-520. doi:10.1097/NMD.0000000000000113

[2] Holze F, Gasser P, Müller F, Dolder PC, Liechti ME. Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biol Psychiatry. 2023;93(3):215-223. doi:10.1016/j.biopsych.2022.08.025

[3] Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol. 2015;29(1):57-68. doi:10.1177/0269881114555249

[4] Grof S, Goodman LE, Richards WA, Kurland AA. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry. 1973;8(3):129-144. doi:10.1159/000467984

​

3,4-methylenedioxymethamphetamine (MDMA)

Post-traumatic stress disorder (PTSD)

[1] Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025-1033. doi:10.1038/s41591-021-01336-3

[2] Mitchell JM, Ot'alora G M, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29(10):2473-2480. doi:10.1038/s41591-023-02565-4

[3] Brewerton TD, Wang JB, Lafrance A, et al. MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. J Psychiatr Res. 2022;149:128-135. doi:10.1016/j.jpsychires.2022.03.008

[4] Jerome L, Feduccia AA, Wang JB, et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2020;237(8):2485-2497. doi:10.1007/s00213-020-05548-2

[5] Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol. 2013;27(1):40-52. doi:10.1177/0269881112464827

[6] Mithoefer MC, Mithoefer AT, Feduccia AA, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018;5(6):486-497. doi:10.1016/S2215-0366(18)30135-4

[7] Van der Kolk BA, Wang JB, Yehuda R, et al. Effects of MDMA-assisted therapy for PTSD on self-experience. PLoS One. 2024;19(1):e0295926. Published 2024 Jan 10. doi:10.1371/journal.pone.0295926

[8] Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study [published correction appears in J Psychopharmacol. 2011 Jun;25(6):852]. J Psychopharmacol. 2011;25(4):439-452. doi:10.1177/0269881110378371

[9] Gorman I, Belser AB, Jerome L, et al. Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder. J Trauma Stress. 2020;33(2):161-170. doi:10.1002/jts.22479

[10] Ponte L, Jerome L, Hamilton S, et al. Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder. J Trauma Stress. 2021;34(4):851-863. doi:10.1002/jts.22696

[11] Bouso JC, Doblin R, Farré M, Alcázar MA, Gómez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs. 2008;40(3):225-236. doi:10.1080/02791072.2008.10400637

[12] Ot'alora G M, Grigsby J, Poulter B, et al. 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. J Psychopharmacol. 2018;32(12):1295-1307. doi:10.1177/0269881118806297

​

Anxiety & end-of-life psychiatric distress/anxiety

[1] Wolfson PE, Andries J, Feduccia AA, et al. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep. 2020;10(1):20442. Published 2020 Nov 24. doi:10.1038/s41598-020-75706-1

[2] Danforth AL, Grob CS, Struble C, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology (Berl). 2018;235(11):3137-3148. doi:10.1007/s00213-018-5010-9

​

Ketamine

Depression

[1] Ahmed GK, Elserogy YM, Elfadl GMA, Ghada Abdelsalam K, Ali MA. Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial. J Affect Disord. 2023;325:127-134. doi:10.1016/j.jad.2023.01.005

[2] Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. doi:10.1001/archpsyc.63.8.856

[3] Correia-Melo FS, Leal GC, Vieira F, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. J Affect Disord. 2020;264:527-534. doi:10.1016/j.jad.2019.11.086

[4] Zavaliangos-Petropulu A, McClintock SM, Khalil J, et al. Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression. J Affect Disord. 2023;333:161-171. doi:10.1016/j.jad.2023.04.015

[5] Payette O, Lespérance P, Desbeaumes Jodoin V, et al. Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series. J Affect Disord. 2023;333:18-20. doi:10.1016/j.jad.2023.04.019

[6] Phillips JL, Norris S, Talbot J, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology. 2020;45(4):606-612. doi:10.1038/s41386-019-0570-x

[7] Abbar M, Demattei C, El-Hage W, et al. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ. 2022;376:e067194. Published 2022 Feb 2. doi:10.1136/bmj-2021-067194

[8] Hochschild A, Keilp JG, Madden SP, Burke AK, Mann JJ, Grunebaum MF. Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression. J Affect Disord. 2022;300:10-16. doi:10.1016/j.jad.2021.12.055

[9] Danayan K, Chisamore N, Rodrigues NB, et al. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder. Psychiatry Res. 2023;323:115133. doi:10.1016/j.psychres.2023.115133

† For the exhaustive list of publications, see: PubMed.

​

Post-traumatic stress disorder (PTSD)

[1] Feder A, Costi S, Rutter SB, et al. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry. 2021;178(2):193-202. doi:10.1176/appi.ajp.2020.20050596

[2] Abdallah CG, Roache JD, Gueorguieva R, et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial [published correction appears in Neuropsychopharmacology. 2022 May 11;:]. Neuropsychopharmacology. 2022;47(8):1574-1581. doi:10.1038/s41386-022-01266-9

​

Functional neurological disorder (FND)

[1] Vendrell-Serres J, Soto-Angona Ó, Rodríguez-Urrutia A, Arteaga-Henríquez G, Ramos-Quiroga JA. Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report. Ther Adv Psychopharmacol. 2021;11:20451253211022187. Published 2021 Jun 16. doi:10.1177/20451253211022187

[2] Argento E, Omene E, Jaeger AH, et al. Case report: Improvement in refractory functional seizures, depression, and quality of life with ketamine-assisted therapy. Front Neurosci. 2023;17:1197409. Published 2023 Jun 12. doi:10.3389/fnins.2023.1197409

​

Borderline personality disorder (BPD)

[1] Fineberg SK, Choi EY, Shapiro-Thompson R, et al. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology. 2023;48(7):991-999. doi:10.1038/s41386-023-01540-4

Cannabis & Epilepsy

Cannabidiol (CBD)

Dravet syndrome

[1] Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011-2020. doi:10.1056/NEJMoa1611618

[2] Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204-e1211. doi:10.1212/WNL.0000000000005254

[3] Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia. 2019;60(2):294-302. doi:10.1111/epi.14628

[4] Scheffer IE, Halford JJ, Miller I, et al. Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial. Epilepsia. 2021;62(10):2505-2517. doi:10.1111/epi.17036

Lennox-Gastaut syndrome (LGS)

[1] Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018;378(20):1888-1897. doi:10.1056/NEJMoa1714631

[2] Patel AD, Mazurkiewicz-Bełdzińska M, Chin RF, et al. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Epilepsia. 2021;62(9):2228-2239. doi:10.1111/epi.17000

[3] Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, et al. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia. 2019;60(3):419-428. doi:10.1111/epi.14670

Tuberous-sclerosis complex (TSC)

[1] Thiele EA, Bebin EM, Bhathal H, et al. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2021;78(3):285-292. doi:10.1001/jamaneurol.2020.4607

[2] Wu JY, Cock HR, Devinsky O, et al. Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6. Epilepsia. 2022;63(5):1189-1199. doi:10.1111/epi.17199

Mixed diagnosis drug-resistant epilepsy cohort

[1] Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial [published correction appears in Lancet Neurol. 2016 Apr;15(4):352]. Lancet Neurol. 2016;15(3):270-278. doi:10.1016/S1474-4422(15)00379-8

CBD + delta-9-tetrahydrocannabinol (THC) 

[1] Nowicki M, Bourgeois-Tardif S, Diaz PL, et al. Potential Benefit of Add-on Δ9-Tetrahydrocannabinol in Pediatric Drug-Resistant Epilepsy: A Case Series. Can J Neurol Sci. 2022;49(4):595-597. doi:10.1017/cjn.2021.151

[2] Erridge S, Holvey C, Coomber R, et al. Clinical Outcome Data of Children Treated with Cannabis-Based Medicinal Products for Treatment Resistant Epilepsy-Analysis from the UK Medical Cannabis Registry. Neuropediatrics. 2023;54(3):174-181. doi:10.1055/a-2002-2119

[3] Huntsman RJ, Tang-Wai R, Alcorn J, et al. Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study. Front Neurol. 2019;10:716. Published 2019 Jul 3. doi:10.3389/fneur.2019.00716

[4] McCoy B, Wang L, Zak M, et al. A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome. Ann Clin Transl Neurol. 2018;5(9):1077-1088. Published 2018 Aug 1. doi:10.1002/acn3.621

bottom of page